xCures

Official Statements

Score contribution: 100 — 3 supporting sources.

Score 1003 references

Featured Reference

Expanded Access to GaM (gallium maltolate)Opens in new window

“xCures and Imaging Biometrics are collaborating on an Expanded Access Protocol (EAP) providing compassionate use of gallium maltolate for participants with relapsed/refractory histologic or molecular glioblastoma who have exhausted standard-of-care therapies.”

PERPETUAL CLINICAL TRIALS Faster, more informative, best for ...Source

“Manage expanded access programs and trials Pay-for-performance program Clearinghouse for EA and off-label therapies Real world data gathering of impact of diagnostics use in decision making”

Reinventing Oncology through AI | xCuresSource

“Manage expanded access programs and trials”

EAP Related Articles from Sponsor

Score contribution: 80 — 5 supporting sources.

Score 805 references

Featured Reference

Jaime Leandro Foundation treats first cancer patient with personalized neoantigen peptide vaccine under expanded access through xCuresOpens in new window

"By partnering with JLF we enabled the use of a personalized neoantigen vaccine under compassionate use/expanded access."

NewsSource

The new registration module facilitates expanded access to novel therapies for patients with advanced cancer while accelerating the generation of real-world data on safety and efficacy.

xCures launches xDECIDE to help oncologists find better treatment options for their patientsSource

The most promising treatments are identified and presented, even when non-traditional methods are needed to access those treatments (e.g., compassionate use program enrollment for an experimental treatment, or; patient assistance for access to a drug or drug combination outside of its primary indication).

xINFORMSource

Trying to enroll in one of our managed access programs?

INNV-37 - XCELSIOR: A real-time, real-world learning platform for ...Source

Interventions include standard-of-care chemotherapies as well as therapies accessed by clinical trial, expanded access, and off-label prescription.

Active EAPs on ClinicalTrials.gov

Score contribution: 60 — 1 supporting sources.

Score 601 references

Featured Reference

Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered MalignanciesOpens in new window

Conditions: Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma, Non Small Cell Lung Cancer, Thyroid Cancer, Bladder Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer, Cholangiocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, MAPK Gene Mutation, KRAS Activating Mutation, BRAF Gene Mutation, NRAS Gene Mutation, HRAS Gene Mutation, MEK Mutation, ERK Mutation

Expanded Access Intelligence

Official Statements

Active EAPs on ClinicalTrials.gov

Reagan-Udall Foundation Insights

Partner with Right2Hope